Annotated highest relative variance abstracts

21154368

Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation.
Elie A Akl, Srinivasa Rao Vasireddi, Sameer Gunukula, Victor E D Yosuico, Maddalena Barba, Irene Terrenato, Francesca Sperati, Holger Schünemann
(Department of Medicine, State University of New York at Buffalo, ECMC CC-142, 462 Grider Street, Buffalo, NY, USA, 14215.)
Cochrane Database Syst Rev

quality vitamin_antagonist anticoagulation search intervention fulfilled evidence electronic_search without oral_anticoagulant efficacy two randomized_controlled participants cause their safety increasing does_not cochrane_library venous_thromboembolism first starting it five web data an using related not volume oral_anticoagulation trials_rcts five_rcts relative_risk years six while isi both moderate compared medline_embase led either inclusion_criteria hematology we references oncology that mortality months with following warfarin bleeding effect improve indication have hypothesis_that bias comprehensive_search benefit_from major_bleeding oral_anticoagulants showed identified_citations reduction one_year comparing was in number controlled_trials therapeutic patients and antithrombotic_effect of increased issue use addition american_society prophylactic placebo may interventions on other rr suggest including feature clinical outcomes pubmed cancer its risk survival article hand one for databases_cochrane at the these extracted rcts central basic_research studies included existing form antitumor_effect through minor_bleeding all no study assessed checking central_register interest science february rr_ci statistically_significant to or standardized

12239453

Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer (stage IIIb or IV) with a higher T stage (> T2). Technetium-99m methoxyisobutylisonitrile chest single photon emission computed tomography and P-glycoprotein express ion.
Wu-Huei Hsu, Ruoh-Fang Yen, Chia-Hung Kao, Shih-Chih Shiun, Nan-Yung Hsu, Cheng-Chieh Lin, Cheng-Chun Lee
(Division of Pulmonary/Critical Care Medicine, Department of Medicine, China Medical College Hospital, Taichung, Taiwan.)
Oncology

t/nl sections tc-mibi difference understand biopsy_specimens ten were prognostic_factors tc-mibi_chest p-glycoprotein_pgp found after early immunohistochemical_analyses paclitaxel multiple_nonconsecutive tumor compare qualitatively after_completion calculated performance_status with quantitatively third_month loss negative can_be could_be stage determine no_significant treatment positive technetium-99m_methoxyisobutylisonitrile detected iv used predict however was in expression student_test poor lung performed evaluated single_photon patients and interpreted of quickly cases chemotherapy radiological +/ spect_images spect enrolled significant body_weight on differences other clinical intravenous_injection age_sex cancer min tomography_spect for emission_computed before chest the these tumor-to-normal an_independent good nsclc pgp this_study aim response between by all stage_iiib groups results type cell to methods or

16733249

Prevention of mouse lung tumors and modulation of DNA methylation by combined treatment with budesonide and R115777 (ZarnestraMT).
Fadel S Alyaqoub, Lianhui Tao, Paula M Kramer, Vernon E Steele, Ronald A Lubet, William T Gunning, Michael A Pereira
(Medical University of Ohio, Toledo OH 43614, USA.)
Carcinogenesis

when longer days/week diet tumor-bearing_mice prevent anti-inflammatory zarnestra them were effective efficacy their after combinations budesonide dna_hypomethylation starting reversal it glucocorticoid an ii albeit administering modulation prevention individual with following whereas reversed received oral_gavage than drugs induced female_strain continued tumors useful administered killing these_results rank_order treatment mice prevented week_later was in lung evaluated and of biomarker farnesyl_transferase more_efficacious endpoint combined use mg/kg_r115777 vinyl_carbamate tipifarnib r115777 other as_surrogate mg/kg produced one for weeks reduced before at the would_be inhibitor dna_methylation by week killings support until_killed no results summary suggest_that preventing later

15896456

The DNA repair gene ERCC2/XPD polymorphism Arg 156Arg (A22541C) and risk of lung cancer in a Chinese population.
Jiaoyang Yin, Jicheng Li, Yegang Ma, Li Guo, Huiwen Wang, Ulla Vogel
(Institute of Cell Biology, Zhejiang University, Hangzhou (310031), Zhejiang Province, People's Republic of China.)
Cancer Lett.

report group 52-20 chinese_population dna_repair consisting cancer ci risk gene subjects a-alleles cancer-free presence one for matched was polymorphism in the associated newly lung among_never-smokers cc_adjusted a-allele two gene-environment_interaction xpd_arg156arg north-eastern with and of stratified_analyses +/-3 possible variant ci_10-5 effect whole increased_risk first control_subjects study not is significant_association ethnicity designed on ci_09-2 age furthermore this hospital-based_case-control years determine gender versus suggest aa/ac to

21113768

Physical activity and lung cancer survivorship.
Lee W Jones
(Department of Surgery, Duke University Medical Center, 3085, Durham, NC 27710, USA. lee.w.jones@duke.edu)
Recent Results Cancer Res.

quality both among role cancer varying_degrees reduce adverse patient common are_warranted operable multidisciplinary_management disease therapy for evidence diagnosed before in the associated that dramatically adjunct poor lung investigating consideration life_qol therapeutic an_adjunct with and increased of age-related_diseases palliation exercise_tolerance as patients after safety studies area putative impairments predisposes tolerate exercise_training pulmonary resection management unique feasible likely carefully susceptibility ability inoperable across here_we physical/functional preliminary supports may_be literature is premature_death continuum exercise other safe this an_important current review prescribed to feasibility diagnosis

15908202

Synthesis, X-ray crystallographic analysis, and antitumor activity of 1-acyl-3,6-disubstituted phenyl-1,4-dihydro-1,2,4,5-tetrazines.
Guo-Wu Rao, Wei-Xiao Hu
(College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, People's Republic of China.)
Bioorg. Med. Chem. Lett.

6-disubstituted calculation therefore results_show vitro phenyl-1 5-tetrazines boat compounds reaction against 2-dihydro from rather_than one six-membered for against_p-388 confirmed in possesses were the derivatives these that structures pm3 central evaluated 4-dihydro two potential and of semi-empirical a-549 their antitumor_activities cells are worth obvious acyl mtt highly_effective single-crystal_x-ray a-549_cells homoaromatic ring conformation by chlorines diffraction yields there further 4-dihydro-1 has

16885199

Prevention of mouse lung tumors and modulation of DNA methylation by combined treatment with budesonide and R115777 (Zarnestra MT).
Fadel S Alyaqoub, Lianhui Tao, Paula M Kramer, Vernon E Steele, Ronald A Lubet, William T Gunning, Michael A Pereira
(Medical University of Ohio, Toledo, OH 43614, USA.)
Carcinogenesis

when longer days/week diet tumor-bearing_mice prevent anti-inflammatory zarnestra them were effective efficacy their after combinations budesonide dna_hypomethylation starting reversal it glucocorticoid an ii albeit administering modulation prevention individual with following whereas reversed received oral_gavage than drugs induced female_strain continued tumors useful administered killing these_results rank_order treatment mice prevented week_later was in lung evaluated end-point and of biomarker farnesyl_transferase more_efficacious combined use mg/kg_r115777 vinyl_carbamate tipifarnib r115777 other as_surrogate mg/kg produced one for weeks reduced before at the would_be inhibitor dna_methylation by week killings support until_killed no results summary suggest_that preventing later

12415683

Characteristic genetic alterations in lung cancer.
Ignacio I Wistuba, Adi F Gazdar
(Department of Pathology, Pontificia Universidad Catolica de Chile, Santiago, Chile.)
Methods Mol. Med.

both recessive_oncogenes advancing_rapidly cancer become mutations common changes while fully_elucidated they subjects new risk from chromosomal_regions for our_understanding preneoplastic_bronchial in before the that tumor-type smoker lung remain dominant genes lead genetic_changes with and patients of chemoprevention identified invasive histologic_types neoplasm early are cumulative undergoing be may_provide response histologic_type epigenetic_changes identification molecular recent each all diagnosis appears such specific appear assessment is those findings normal several monitoring this suggest_that tumor pathology others neoplastic require to many sequence epithelium

23736019

A meta-analysis of the association between glutathione S-transferase P1 gene polymorphism and the risk of adenocarcinomas of lung cancer.
Hong Zhong, Yi Feng, Gui-Xiong Zheng, Yan Liang, Jun-Yuan Zhang, Bao-Shi Zheng, Xu Feng
(Department of Cardio-Thoracic Surgery, People's Hospital of Beihai, Beihai, China.)
Cancer Biomark

pubmed p1_gstp1 cancer risk synthesized non-sensitivity gene from adenocarcinomas for was glutathione_s-transferase polymorphism in the were associated lung performed gg_genotype with and of biomarker identified studies included are cochrane_library association_between into be gstp1_a/g eligible susceptibility still_debated gstp1 meta-analysis results reports using not is those association method analysis on published_reports this investigations allele furthermore similar to sensitivity or

11217455

Molecular pathology of lung cancer.
I I Wistuba, A F Gazdar
(Department of Pathology, Pontificia Universidad Catolica de Chile, Santiago, P.O. Box 114-D, Chile.)
Verh Dtsch Ges Pathol

both recessive_oncogenes advancing_rapidly cancer become mutations common changes while fully_elucidated they subjects new risk from chromosomal_regions for our_understanding preneoplastic_bronchial in before the that smoker lung remain dominant genes lead genetic_changes with and patients of chemoprevention identified invasive histologic_types neoplasm early are cumulative undergoing be may_provide response histologic_type epigenetic_changes identification molecular recent each all diagnosis appears type specific appear such is assessment those findings normal several monitoring this suggest_that tumor pathology others neoplastic require to many sequence epithelium methods